<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<!-- saved from url=(0130)http://www.clinicalevidenceonline.org/lpBinCE/lpext.dll/BMJSPLITCE/cvd.html/0204/0204_q2/0204_i1?fn=document-frame.htm&f=templates -->
<HTML><HEAD><TITLE>Clinical Evidence</TITLE>
<META http-equiv=Content-Type content="text/html; charset=windows-1252"><LINK 
href="0204_i1_files/bmj.css" type=text/css rel=stylesheet>
<META content="MSHTML 5.50.4807.2300" name=GENERATOR></HEAD>
<BODY topMargin=0>
<TABLE cellSpacing=0 borderColorDark=#ffffff cellPadding=0 width="100%" 
borderColorLight=#c2c2c2 border=1>
  <TBODY>
  <TR>
    <TD class=heading id=heading>
      <SCRIPT src="0204_i1_files/0204_i1.0"></SCRIPT>

      <SCRIPT language=JavaScript> function showWindow(targeturl) { window.open(targeturl, ""); } </SCRIPT>

      <TABLE width="100%" border=0>
        <TBODY>
        <TR>
          <TD align=right><SPAN class=localheadtopic 
            id=localheadtopic><SECTION>Cardiovascular 
            disorders</SECTION></SPAN><IMG height=10 
            src="0204_i1_files/spacer.gif" width=10 align=absMiddle 
            border=0><BR><SPAN class=localhead id=localhead><TOPIC>Heart 
            failure</TOPIC><IMG height=10 src="0204_i1_files/spacer.gif" 
            width=10 align=absMiddle border=0></SPAN></TD></TR>
        <TR>
          <TD class=title-author id=title-author vAlign=top noWrap align=right 
          bgColor=#ffffff height=30><A 
            href="http://www.clinicalevidenceonline.org/lpBinCE/lpext.dll?f=id&amp;id=0204_CONTRIB&amp;t=document-frame.htm&amp;2.0&amp;p=">Robert 
            McKelvie</A><IMG height=10 src="0204_i1_files/spacer.gif" width=10 
            align=absMiddle border=0></TD></TR></TBODY></TABLE><BR>
      <H1 style="DISPLAY: none; FONT-SIZE: 0pt; VISIBILITY: hidden">Drug 
      treatments</H1>
      <TABLE cellSpacing=0 cellPadding=3 width="100%" border=0>
        <TBODY>
        <TR>
          <TD class=question id=question vAlign=top width="10%"><B><SPAN 
            class=question-title id=question-title>QUESTION</SPAN></B></TD>
          <TD class=question id=question>&nbsp;<B>What are the effects of drug 
            treatments in heart failure?</B></TD></TR></TBODY></TABLE><BR><A name=I1>
      <H2 style="DISPLAY: none; FONT-SIZE: 0pt; VISIBILITY: hidden">ACE 
      inhibitors</H2>
      <TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
        <TBODY>
        <TR class=option id=option>
          <TD class=option id=option style="PADDING-LEFT: 2px" vAlign=top 
          width="10%"><SPAN class=option-title 
            id=option-title>OPTION&nbsp;&nbsp;&nbsp;</SPAN></TD>
          <TD class=option id=option style="PADDING-LEFT: 2px" 
            width="100%"><B>Angiotensin converting enzyme (ACE) 
        inhibitors</B></TD></TR></TBODY></TABLE></A>
      <TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
        <TBODY>
        <TR>
          <TD><A name=I1-SUMSTATEMENT><B>
            <P style="MARGIN-LEFT: 3px" align=justify>Two systematic reviews and 
            recent RCTs have found that ACE inhibitors reduce mortality, 
            admission to hospital for heart failure, and ischaemic events in 
            people with heart failure. Relative benefits are similar in 
            different groups of people, but absolute benefits are greater in 
            people with severe heart 
failure.</P></B></A></TD></TR></TBODY></TABLE><BR>
      <TABLE cellSpacing=0 cellPadding=3 width="100%" border=0>
        <TBODY>
        <TR>
          <TD>
            <P align=justify><FONT color=#0033cc><A 
            name=I1-BENEFITS><B>Benefits: </B></A></FONT>We found two systematic 
            reviews of ACE inhibitors versus placebo in heart failure. <A 
            href="http://www.clinicalevidenceonline.org/lpBinCE/lpext.dll/BMJSPLITCE/cvd.html/0204/0204_q2/0204_i1?fn=document-frame.htm&amp;f=templates#REF20">[20]</A> 
            <A 
            href="http://www.clinicalevidenceonline.org/lpBinCE/lpext.dll/BMJSPLITCE/cvd.html/0204/0204_q2/0204_i1?fn=document-frame.htm&amp;f=templates#REF21">[21]</A> 
            The first systematic review (search date 1994, 32 RCTs, duration 
            3–42 months, 7105 people, NYHA class II or worse [<A 
            href="http://www.clinicalevidenceonline.org/lpBinCE/lpext.dll?f=id&amp;id=0204_GLOSSARY&amp;t=document-frame.htm&amp;2.0&amp;p=#G1">see 
            glossary<IMG height=15 
            src="0204_i1_files/anchor-arrow-12x15-navy.gif" width=12 
            align=absMiddle border=0></A>] <A 
            href="http://www.clinicalevidenceonline.org/lpBinCE/lpext.dll/BMJSPLITCE/cvd.html/0204/0204_q2/0204_i1?fn=document-frame.htm&amp;f=templates#REF20">[20]</A> 
            found that ACE inhibitors versus placebo reduced mortality (611/3870 
            [16%] with ACE inhibitors <EM>v</EM> 709/3235 [22%] with placebo; 
            ARR 6%, 95% CI 4% to 8%; OR 0.77, 95% CI 0.67 to 0.88; NNT 16). 
            Relative reductions in mortality were similar in different subgroups 
            (stratified by age, sex, cause of heart failure, and NYHA class). 
            The second systematic overview (search date not stated, 5 RCTs, 
            12&nbsp;763 people with left ventricular dysfunction or heart 
            failure, mean duration 35 months) analysed results from individuals 
            in long term and large RCTs that compared ACE inhibitors versus 
            placebo. <A 
            href="http://www.clinicalevidenceonline.org/lpBinCE/lpext.dll/BMJSPLITCE/cvd.html/0204/0204_q2/0204_i1?fn=document-frame.htm&amp;f=templates#REF21">[21]</A> 
            Three RCTs were in people for 1 year after myocardial infarction. In 
            these three post infarction trials (5966 people), ACE inhibitor 
            versus placebo significantly reduced mortality (702/2995 [23.4%] 
            <EM>v</EM> 866/2971 [29.1%]; OR 0.74, 95% CI 0.66 to 0.83), 
            re-admission for heart failure (355/2995 [11.9%] <EM>v</EM> 460/2971 
            [15.5%]; OR 0.73, 95% CI 0.63 to 0.85), and reinfarction (324/2995 
            [10.8%] <EM>v</EM> 391/2971 [13.2%]; OR 0.80, 95% CI 0.69 to 0.94]). 
            For all five trials, ACE inhibitors versus placebo reduced mortality 
            (1467/6391 [23.0%] <EM>v</EM> 1710/6372 [26.8%]; OR 0.80, 95% CI 
            0.74 to 0.87), reinfarction (571/6391 [8.9%] <EM>v</EM> 703/6372 
            [11.0%]; OR 0.79, 95% CI 0.70 to 0.89), and re-admission for heart 
            failure (876/6391 [13.7%] <EM>v</EM> 1202/6372 [18.9%]; OR 0.67, 95% 
            CI 0.61 to 0.74). The benefits began soon after the start of 
            therapy, persisted long term, were independent of age, sex, and 
            baseline use of diuretics, aspirin, and ß blockers. Although there 
            was a trend towards greater relative reduction in mortality or 
            re-admission for heart failure in people with lower ejection 
            fractions, benefit was apparent over the range examined. <B>Other 
            ischaemic events:</B> Individual RCTs that studied high risk groups 
            found that ACE inhibitors significantly reduced some ischaemic event 
            rates. One RCT in people with left ventricular dysfunction found 
            that, compared with placebo, ACE inhibitors reduced myocardial 
            infarction (combined fatal or non-fatal myocardial infarction: 9.9% 
            <EM>v</EM> 12.3%; RRR 23%, 95% CI 2% to 39%), hospital admission for 
            angina (15% <EM>v</EM> 19%; RRR 27%, 95% CI 12% to 40%), and the 
            combined end point of cardiac death, non-fatal myocardial 
            infarction, or hospital admission for angina (43% <EM>v</EM> 51%; 
            RRR 23%, 95% CI 14% to 32%). <A 
            href="http://www.clinicalevidenceonline.org/lpBinCE/lpext.dll/BMJSPLITCE/cvd.html/0204/0204_q2/0204_i1?fn=document-frame.htm&amp;f=templates#REF9">[9]</A> 
            Effects on hospital re-admissions were observed shortly after 
            starting ACE inhibitor treatment, although effects on ischaemic 
            events were not apparent for at least 6 months and peaked at 36 
            months. <B>Dosage:</B> We found one large RCT (3164 people with <A 
            href="http://www.clinicalevidenceonline.org/lpBinCE/lpext.dll?f=id&amp;id=0204_GLOSSARY&amp;t=document-frame.htm&amp;2.0&amp;p=#G1">NYHA 
            class II-IV heart failure<IMG height=15 
            src="0204_i1_files/anchor-arrow-12x15-navy.gif" width=12 
            align=absMiddle border=0></A>), which compared low dose lisinopril 
            (2.5&nbsp;mg or 5.0&nbsp;mg daily) versus high dose lisinopril 
            (32.5&nbsp;mg or 35&nbsp;mg daily). <A 
            href="http://www.clinicalevidenceonline.org/lpBinCE/lpext.dll/BMJSPLITCE/cvd.html/0204/0204_q2/0204_i1?fn=document-frame.htm&amp;f=templates#REF22">[22]</A> 
            It found no significant difference in mortality (717/1596 [44.9%] 
            with low dose <EM>v</EM> 666/1568 [42.5%] with high dose; ARR 8%, 
            95% CI not given; hazard ratio 0.92, 95% CI 0.80 to 1.03; 
            P&nbsp;=&nbsp;0.128), but found that high dose lisinopril reduced 
            the combined outcome of death or hospital admission for any reason 
            (1338 events with low dose [83.8%] <EM>v</EM> 1250 events with high 
            dose [79.7%]; ARR 12%; hazard ratio 0.88, 95% CI 0.82–0.96; 
            P&nbsp;=&nbsp;0.002) and reduced admissions for heart failure (1576 
            admissions with low dose <EM>v</EM> 1199 admissions with high dose; 
            ARR 24%; P&nbsp;=&nbsp;0.002). <B>Comparison of different ACE 
            inhibitors: </B>The first systematic review found similar benefits 
            with different ACE inhibitors. <A 
            href="http://www.clinicalevidenceonline.org/lpBinCE/lpext.dll/BMJSPLITCE/cvd.html/0204/0204_q2/0204_i1?fn=document-frame.htm&amp;f=templates#REF20">[20]</A> 
            </P></TD></TR></TBODY></TABLE>
      <TABLE cellSpacing=0 cellPadding=3 width="100%" border=0>
        <TBODY>
        <TR>
          <TD>
            <P align=justify><FONT color=#0033cc><A name=I1-HARMS><B>Harms: 
            </B></A></FONT>We found no systematic review. The main adverse 
            effects documented in large trials were cough, hypotension, 
            hyperkalaemia, and renal dysfunction. Compared with placebo, ACE 
            inhibitors increased the incidence of cough (37% <EM>v</EM> 31%; ARI 
            7%, 95% CI 3% to 11%; RRI 23%, 95% CI 11% to 35%; NNH 14), dizziness 
            or fainting (57% <EM>v</EM> 50%; ARI 7%, 95% CI 3% to 11%; RRI 14%, 
            95% CI 6% to 21%; NNH 14), increased creatinine concentrations above 
            177&nbsp;µmol/litre (10.7% <EM>v</EM> 7.7%; ARI 3%, 95% CI 0.6% to 
            6%; RRI 38%, 95% CI 9% to 67%; NNH 34), and increased potassium 
            concentrations above 5.5&nbsp;mmol/litre (ARs 6.4% <EM>v</EM> 2.5%; 
            ARI 4%, 95% CI 2% to 7%; RRI 156%, 95% CI 92% to 220%; NNH 26). <A 
            href="http://www.clinicalevidenceonline.org/lpBinCE/lpext.dll/BMJSPLITCE/cvd.html/0204/0204_q2/0204_i1?fn=document-frame.htm&amp;f=templates#REF23">[23]</A> 
            Angioedema was not found to be more common with ACE inhibitors than 
            placebo (3.8% taking enalapril <EM>v</EM> 4.1% taking placebo; ARI 
            +0.3%, 95% CI –1.4% to +1.5%). <A 
            href="http://www.clinicalevidenceonline.org/lpBinCE/lpext.dll/BMJSPLITCE/cvd.html/0204/0204_q2/0204_i1?fn=document-frame.htm&amp;f=templates#REF23">[23]</A> 
            The trial comparing low and high doses of lisinopril found that most 
            adverse effects were more common with high dose (no P value 
            reported; dizziness: 12% with low dose <EM>v</EM> 19% with high 
            dose; hypotension: 7% with low dose <EM>v</EM> 11% with high dose; 
            worsening renal function: 7% with low dose <EM>v</EM> 10% with high 
            dose; significant change in serum potassium concentration: 7% with 
            low dose <EM>v</EM> 7% with high dose), although there was no 
            difference in withdrawal rates between groups (17% discontinued with 
            high dose <EM>v</EM> 18% with low dose). The trial found that cough 
            was less commonly experienced with high dose compared with low dose 
            lisinopril (cough: 13% with low dose <EM>v</EM> 11% with high 
            dose).</P></TD></TR></TBODY></TABLE>
      <TABLE cellSpacing=0 cellPadding=3 width="100%" border=0>
        <TBODY>
        <TR>
          <TD>
            <P align=justify><FONT color=#0033cc><A name=I1-COMMENT><B>Comment: 
            </B></A></FONT>The relative beneficial effects of ACE inhibitors 
            were similar in different subgroups of people with heart failure. 
            Most RCTs evaluated left ventricular function by assessing LVEF, but 
            some studies defined heart failure clinically, without measurement 
            of left ventricular function in people at high risk of developing 
            heart failure (soon after myocardial infarction). It is unclear 
            whether there are additional benefits from adding ACE inhibitor 
            therapy to people with heart failure who are already taking 
            antiplatelet therapy, and of adding antiplatelet therapy to people 
            with heart failure who are already taking an ACE inhibitor (<A 
            href="http://www.clinicalevidenceonline.org/lpBinCE/lpext.dll?f=id&amp;id=0204_I12&amp;t=document-frame.htm&amp;2.0&amp;p=#I12">see 
            antiplatelet agents</A>).</P></TD></TR></TBODY></TABLE><BR><A 
      name=references></A>
      <TABLE cellSpacing=0 cellPadding=0 border=0>
        <TBODY>
        <TR>
          <TD width=90 bgColor=#404040><IMG height=2 src="" width=1 
            align=absMiddle border=0></TD>
          <TD vAlign=bottom width="100%" bgColor=#404040><IMG height=2 src="" 
            width=1 align=absMiddle border=0></TD></TR>
        <TR>
          <TD class=key-message id=key-message width=90 
            bgColor=#404040><B>References</B></TD>
          <TD width="100%">&nbsp;</TD></TR></TBODY></TABLE><BR>
      <TABLE cellPadding=2 width="100%" align=center>
        <TBODY>
        <TR><A class=reference id=reference name=REF9>
          <TD class=reference id=reference vAlign=top width=15>9. </TD>
          <TD class=reference id=reference vAlign=top width="100%">Yusuf S, 
            Pepine CJ, Garces C, et al. Effect of enalapril on myocardial 
            infarction and unstable angina in patients with low ejection 
            fractions. <EM>Lancet</EM> 1992;340:1173–1178. <A 
            style="FONT-SIZE: 8pt" 
            href='javascript:showWindow("http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=93061581");'>[PubMed]</A></TD></TR>
        <TR></A><A class=reference id=reference name=REF20>
          <TD class=reference id=reference vAlign=top width=15>20. </TD>
          <TD class=reference id=reference vAlign=top width="100%">Garg R, 
            Yusuf S, for the Collaborative Group on ACE Inhibitor Trials. 
            Overview of randomized trials of angiotensin-converting enzyme 
            inhibitors on mortality and morbidity in patients with heart 
            failure. <EM>JAMA</EM> 1995;273:1450–1456. Search date 1994; primary 
            sources Medline; correspondence with investigators and 
            pharmaceutical firms. <A style="FONT-SIZE: 8pt" 
            href='javascript:showWindow("http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=95239885");'>[PubMed]</A></TD></TR>
        <TR></A><A class=reference id=reference name=REF21>
          <TD class=reference id=reference vAlign=top width=15>21. </TD>
          <TD class=reference id=reference vAlign=top width="100%">Flather M, 
            Yusuf S, Kober L, et al, for the ACE-Inhibitor Myocardial Infarction 
            Collaborative Group. Long-term ACE-inhibitor therapy in patients 
            with heart failure or left-ventricular dysfunction: a systematic 
            overview of data from individual patients. <EM>Lancet</EM> 
            2000;355:1575–1581. Search date not stated; primary sources Medline; 
            Ovid; and hand searches of reference lists and personal contact with 
            researchers, colleagues and principal investigators of the trials 
            identified. <A style="FONT-SIZE: 8pt" 
            href='javascript:showWindow("http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20279380");'>[PubMed]</A></TD></TR>
        <TR></A><A class=reference id=reference name=REF22>
          <TD class=reference id=reference vAlign=top width=15>22. </TD>
          <TD class=reference id=reference vAlign=top width="100%">Packer M, 
            Poole-Wilson PA, Armstrong PW, et al, on behalf of the ATLAS Study 
            Group. Comparative effects of low and high doses of the 
            angiotensin-converting enzyme inhibitor, lisinopril, on morbidity 
            and mortality in chronic heart failure. <EM>Circulation</EM> 
            1999;100:2312–2318. <A style="FONT-SIZE: 8pt" 
            href='javascript:showWindow("http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20054130");'>[PubMed]</A></TD></TR>
        <TR></A><A class=reference id=reference name=REF23>
          <TD class=reference id=reference vAlign=top width=15>23. </TD>
          <TD class=reference id=reference vAlign=top width="100%">SOLVD 
            Investigators. Effect of enalapril on survival in patients with 
            reduced left ventricular ejection fractions and congestive heart 
            failure. <EM>N Engl J Med</EM> 1991;325:293–302. <A 
            style="FONT-SIZE: 8pt" 
            href='javascript:showWindow("http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=91278933");'>[PubMed]</A></TD></TR></TBODY></TABLE>
      <TABLE width="100%" border=0>
        <TBODY>
        <TR>
          <TD vAlign=bottom width="50%">
          <TD align=right width="50%"><A 
            href="http://www.clinicalevidenceonline.org/lpBinCE/lpext.dll?f=id&amp;id=201106&amp;t=document-frame.htm&amp;p=copyright.html&amp;2.0"><IMG 
            alt="BMJ - Clinical Evidence" src="0204_i1_files/ce-pagebrand.jpg" 
            border=0></A></TD></TR>
        <TR>
          <TD align=left width="50%">
          <TD align=right width="50%"><A 
            href="http://www.clinicalevidenceonline.org/lpBinCE/lpext.dll?f=id&amp;id=201106&amp;t=document-frame.htm&amp;p=copyright.html&amp;2.0"><SPAN 
            style="FONT-SIZE: 8pt; font-face: arial">© 2001 BMJ Publishing 
            Group</SPAN></A></TD></TR></TBODY></TABLE>
      <SCRIPT language=JavaScript>
			var purl = "0204.PDF"; 
</SCRIPT>

      <SCRIPT language=JavaScript src="0204_i1_files/stats.js" 
      type=text/javascript></SCRIPT>

      <SCRIPT language=JavaScript type=text/javascript><!--
  stats("MC-MTg0OQ==-45MT-Y2Nz","","","");
//--></SCRIPT>
      <NOSCRIPT><IMG height=1 src="" width=1 
  border=0></NOSCRIPT></A></TD></TR></TBODY></TABLE>
<FORM name=LPHitCountForm><INPUT type=hidden value=0 name=LPHitCount> 
</FORM></BODY></HTML>
